South Korea Parp Inhibitor Biomarkers Market Size & Outlook

The parp inhibitor biomarkers market in South Korea is expected to reach a projected revenue of US$ 54.5 million by 2030. A compound annual growth rate of 10.3% is expected of South Korea parp inhibitor biomarkers market from 2024 to 2030.
Revenue, 2023 (US$M)
$27.4
Forecast, 2030 (US$M)
$54.5
CAGR, 2024 - 2030
10.3%
Report Coverage
South Korea

South Korea parp inhibitor biomarkers market, 2018-2030 (US$M)

South

South Korea parp inhibitor biomarkers market highlights

  • The South Korea parp inhibitor biomarkers market generated a revenue of USD 27.4 million in 2023 and is expected to reach USD 54.5 million by 2030.
  • The South Korea market is expected to grow at a CAGR of 10.3% from 2024 to 2030.
  • In terms of segment, kits was the largest revenue generating product in 2023.
  • Assays is the most lucrative product segment registering the fastest growth during the forecast period.


Parp inhibitor biomarkers market data book summary

Market revenue in 2023USD 27.4 million
Market revenue in 2030USD 54.5 million
Growth rate10.3% (CAGR from 2023 to 2030)
Largest segmentKits
Fastest growing segmentAssays
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationKits, Assays
Key market players worldwideMyriad Genetics Inc, Ambry Genetics, Thermo Fisher Scientific Inc, Illumina Inc, Centogene NV Ordinary Shares, Amoy Diagnostics, Invitae Corp, NeoGenomics, Qiagen NV, Agilent Technologies Inc


Other key industry trends

  • In terms of revenue, South Korea accounted for 2.6% of the global parp inhibitor biomarkers market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China parp inhibitor biomarkers market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 101.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

PARP Inhibitor Biomarkers Market Scope

Parp inhibitor biomarkers market segmentation & scope
Kits
Assays
BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Other Services
Breast Cancer
Ovarian Cancer
Other Application

PARP Inhibitor Biomarkers Market Companies

Name Profile # Employees HQ Website

South Korea parp inhibitor biomarkers market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to parp inhibitor biomarkers market will help companies and investors design strategic landscapes.


Kits was the largest segment with a revenue share of 65.33% in 2023. Horizon Databook has segmented the South Korea parp inhibitor biomarkers market based on kits, assays covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to South Korea parp inhibitor biomarkers market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of South Korea parp inhibitor biomarkers market databook

  • Our clientele includes a mix of parp inhibitor biomarkers market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the South Korea parp inhibitor biomarkers market, including forecasts for subscribers. This country databook contains high-level insights into South Korea parp inhibitor biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

South Korea parp inhibitor biomarkers market report size, by product, 2018-2030 (US$M)

South Korea PARP Inhibitor Biomarkers Market Share, 2023 & 2030 (US$M)

South Korea parp inhibitor biomarkers market report size, by product, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more